New Aspects on the Natural History of Chronic Hepatitis B Infection: Implication for Therapy

References

• Gjørup IE, Skinhøj P, Böttiger B, Plesner A-M. Changing epidemiology of HBV infection in Danish children. J Infect 2003; 47: 231–5
   PubMed Web of Science ®Google Scholar
• Lee WM, Hepatitis B. virus infection. N Engl J Med 1997; 337: 1733–45.
   PubMed Web of Science ®Google Scholar
• Sanchez-Tapias JM, Costa J, Mas A, Bruguera M, Rodes J. Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in Western patients. Gastroenterol 2002; 123: 1848–56.
   PubMed Web of Science ®Google Scholar
• Bortolotti F, Jara P, Crivellaro C, Hierro L, Cadrobbi P, Franca E, et al. Outcome of chronic hepatitis B in Caucasian children during a 20 y observation period. J of Hepatol 1998; 29: 184–90.
   PubMed Web of Science ®Google Scholar
• Villeneuve J-P, Desrochers M, Infante-Rivard C, Willems B, Raymond G, Bourcier M, et al. A long-term follow-up study of asymptomatic hepatitis B surface antigen-positive carriers in Montreal. Gastroenterol 1994; 106: 1000–5.
   PubMed Web of Science ®Google Scholar
• de Franchis R, Meucci G, Vecchi M, Tatarella M, Colombo M, Del Ninno E, et al. The natural history of asymptomatic hepatitis B surface antigen carriers. Ann Intern Med 1993; 118: 191–4.
   Google Scholar
• Norman JE, Beebe GW, Hoofnagle JH, Seef LB. Mortality follow-up of the 1942 epidemic of hepatitis B in the US Army. Hepatol 1993; 18: 790–7.
   PubMedGoogle Scholar
• Marx G, Martin SR, Chicoine J-F, Alvarez F. Long-term follow-up of chronic hepatitis B virus infection in children of different ethnic origins. J Infect Dis 2002; 186: 295–301.
   Google Scholar
• Evans AA, Fine M, London WT. Spontaneous seroconversion in hepatitis Be antigen-positive chronic hepatitis B: implications for interferon therapy. J Inf Dis 1997; 176: 845–50.
   Google Scholar
• Fattovichd KG, Rugge M, Brollo L, Pontisso P, Noventa F, Guido M, et al. Clinical, virological and histological outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis B type B. Hepatology 1986; 6: 167–72.
   PubMedGoogle Scholar
• Lok ASF. Chronic hepatitis B. N Engl J Med 2002; 346: 1682–3.
   PubMed Web of Science ®Google Scholar
• Hyams KC. Risk of chronicity following acute hepatitis B virus infection: a review. Clin Inf Dis 1995; 20: 992–1000.
   PubMed Web of Science ®Google Scholar
• Kaganov BS, Nisevich NI, Uchaikin VF, Konev VA, Levina EJ, et al. Acute viral hepatitis B in children: lack of chronicity (letter). Lancet 1990; 336: 374–5.
   PubMedGoogle Scholar
• McMahon BJ, Holck P, Bulkow L, Snowball M. Serological and clinical outcomes of 1536 Alaska natives chronically infected with hepatitis B virus. Ann Intern Med 2001; 135: 759–68.
   PubMed Web of Science ®Google Scholar
• Lok ASF, Lai CA. A longitudinal follow-up of asymptomatic hepatitis B surface antigen-positive Chinese children. Hepatology 1988; 8: 1130–3.
   PubMedGoogle Scholar
• Nielsen JO, Dietrichson O, Elling P, Christoffersen P. Incidence and meaning of persistence of Australia antigen in patients with acute viral hepatitis: development of chronic hepatitis. N Eng J Med 1971; 285: 1157–60.
   PubMed Web of Science ®Google Scholar
• Redeker AG. Viral hepatitis: clinical aspects. Am J Med Sci 1975; 270: 9–16.
   PubMed Web of Science ®Google Scholar
• McMahon BJ, Alward WLM, Hall DB, Heyward WL, Bender TR, Francis DP, Maynard JE. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis 1985; 106: 843–9.
   Google Scholar
• Gocke DJ. A prospective study of post-transfusion hepatitis: the role of Australia antigen. JAMA 1972; 219: 1165–70.
   PubMed Web of Science ®Google Scholar
• Tassopoulos NC, Papaevangelou GJ, Sjogren MH, Roumeliotou-Karayannis A, Gerin JL, Purcell RH. Natural history of acute hepatitis B surface antigen-positive hepatitis in Greek adults. Gastroenterology 1987; 92: 1844–50.
   Google Scholar
• Seef LB, Beebe GW, Hoofnagle JH, Normann JE, Buskell-Bales Z, et al. A serological follow-up of the 1942 epidemic of postvaccination hepatitis in the US Army. N Eng J Med 1987; 316: 965–70.
   Google Scholar
• Yang HI, Lu S-N, Liaw Y-F, You S-L, Sun C-A, et al. Hepatitis Be-antigen and the risk for hepatocellular carcinoma. N Eng J Med 2002; 347: 168–74.
   PubMed Web of Science ®Google Scholar
• De Jongh FE, Janssen HLA, De Man RA, Hop WCJ, Schalm SW, von Blankenstein MV. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992; 103: 1630–5.
   Google Scholar
• Weissberg JI, Andres LL, Smith CI, Weick S, Nichols JE, Garcia G, et al. Survival in chronic hepatitis B. Ann Intern Med 1984; 101: 613–6.
   PubMed Web of Science ®Google Scholar
• Sakuma K, Saitok N, Kasai M, Jitsukawa H, Yshino I, et al. Relative risk and death due to liver disease among Japanese male adults having various statuses for hepatitis Bs and e antigen/antibody in serum; a prospective study. Hepatol 1988; 8: 1642–6.
   PubMedGoogle Scholar
• Fujisawa T, Komatsu H, Inui A, Sogo T, Miyagawa Y, et al. Long-term outcome of chronic hepatitis in adolescents or young adults in follow-up from childhood. J Pediatr Gastroenterol Nutr 2000; 30: 201–6.
   PubMed Web of Science ®Google Scholar
• Bortolotti F, Cadrobbi P, Crivellaro C, Guido M, Rugge M, et al. Long-term outcome of chronic type B hepatitis in patients who acquire hepatitis B virus infection in childhood. Gastroenterology 1990; 99: 805–10.
   PubMed Web of Science ®Google Scholar
• Dragosic B, Ferenci P, Hitcham E, Denk H. Long-term followup study of asymptomatic HBsAg-positive voluntary blood donors in Austria: a clinical and histological evaluation of 242 cases. Hepatol 1987; 7: 302–6.
   PubMedGoogle Scholar
• Fattovich G, Brollo L, Guistina G, Noventa F, Pontisso P, et al. Natural history and prognostic factors for chronic hepatitis type B. Gut 1991; 32: 294–8.
   PubMed Web of Science ®Google Scholar
• Liaw YF, Tai DI, Chu CM, Chen TJ. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1988; 8: 493–6.
   PubMed Web of Science ®Google Scholar
• Funk ML, Rosenberg DM, Lok ASF. Worldwide epidemiology of HB_eAg-negative chronic hepatitis B and associated precore and core promotor variants. J Viral Hep 2002; 9: 52–61.
   Google Scholar
• Hadziyannis SJ. Hepatitis Be antigen negative chronic hepatitis B. From clinical recognition to pathogenesis and treatment. Viral Hep Rev 1995; 1: 7–36.
   Google Scholar
• Di Marco, Iacona OL, Camma C, Vaccaro A, Guinta M, et al. The long-term course of chronic hepatitis B. Hepatology 1999; 30: 257–64.
   PubMedGoogle Scholar
• Hadziyannis S, Bramou T, Markris A, Moussoulis G, Zignego L, Papaioannou C. Interferon alfa-2b treatment of HBeAg negative/serum HBV DNA positive chronic active hepatitis type B. J Hepatol 1990; II: S133–6.
   Google Scholar
• Lok ASF, Akarca US, Greene S. Predictive value of precore hepatitis B virus mutations in spontaneous and interferoninduced hepatitis B_e antigen clearence. Hepatology 1995; 21: 19–24.
   Google Scholar
• Erhardt A, Reineke U, Blondin D, Gerlich WH, Adams O, et al. Mutations of the core promotor and response to interferon treatment in chronic replicative hepatitis B. Hepatology 2000; 31: 716–25.
   PubMed Web of Science ®Google Scholar
• Wong FS, Fung S, Lok ASF, Hussein M. Use of lamivudine in Chinese patients with hepatitis Be-antigen negative chronic hepatitis B. Hepatology 2000; 32: A 864.
   Google Scholar
• Kao J-H, Chen P-J, Lai M-Y, Chen D-S. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000; 118: 554–9.
   PubMed Web of Science ®Google Scholar
• Fujie H, Moriya K, Shintani Y, Yotsuyanagi H, Ilno S, et al. Hepatitis B virus and hepatocellular carcinoma in Japan (letter). Gastroenterology 2001; 120: 1564.
   PubMedGoogle Scholar
• Shaw T, Bowden S, Locarnini S. Chemotherapy for hepatitis B: new treatment options necessitate reappraisal of traditional endpoints. Gastroenterology 2002; 123: 2135–40.
   Google Scholar
• Krogsgaard K, Bindslev N, Christensen E, Crax A, Schlicting P, et al. The treatment effect of alpha interferon in chronic hepatitis B is independent of pre-treatment variables. Results based on individual patient data from 10 clinical controlled trials. J Hepatol 1994; 21: 646–55.
   Google Scholar
• Lok ASF, McMahon BJ. Chronic hepatitis B. Hepatology 2001; 34: 1225–41.
   PubMed Web of Science ®Google Scholar
• Jonas MM, Kelley DA, Miserski J, Badia IB, Areias JA, et al. Clinical trial of lamivudine in children with chronic hepatitis B. New Eng J Med 2002; 346: 1706–13.
   PubMed Web of Science ®Google Scholar
• Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, et al. Efficacy of lamivudine in patients with hepatitis Be antigen – negative/hepatitis B virus DNA positive (precore mutant) chronic hepatitis B. Lamivudine precore mutant study group. Hepatology 1999; 29: 889–96.
   Google Scholar
• Marcellin P, Chang T-T, Lim SG, Tong MJ, Sievert W. Adefovir dipivoxil for the treatment of hepatitis Be antigen-positive chronic hepatitis B. New Eng J Med 2003; 348: 808–16.
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang T-T, Kitis G, et al. Adefovir dipivoxil for the treatment of hepatitis B_e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348: 800–7.
   Google Scholar
• Benhamou Y, Tubiana R, Thibault V Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus. N Eng J Med 2003; 348: 177–8.
   PubMed Web of Science ®Google Scholar
• Nelson M, Stebbing J, Atkins M, Barr A, Matthews G, et al. An open-label study of tenofovir in HIV-1 and hepatitis B virus coinfected individuals. AIDS 2003; 17: F7–F10.
   Google Scholar
• Lai C-L, Rosmawati M, Lao J, van Vlierberghe H, Anderson FH, et al. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 2002; 123: 1831–8.
   PubMed Web of Science ®Google Scholar
• Levine S, Hernandez D, Yamanaka G, Zhang S, Rose R, et al. Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob Agents Chemother 2002; 46: 2525–32.
   PubMed Web of Science ®Google Scholar
• Yalcin K, Degertekin H, Yildiz F, Celik Y. Comparison of 12 months courses of interferon-α-2b-lamivudine combination therapy and interferon-α-2b-monotherapy among patients with untreated chronic hepatitis B. Clin Inf Dis 2003; 36: 1516–22.
   PubMedGoogle Scholar
• EASL Jury. EASL International consensus conference on hepatitis B. J Hepatol 2003; 38: 533–40.
   PubMedGoogle Scholar
• Mommeja-Marin H, Mondou E, Blum MR, Rousseau F. Serum HBV-DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology 2003; 37: 1309–19.
   PubMed Web of Science ®Google Scholar